Drug intelligence / Profile preview

ZKA78

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

**ZKA78** is a human monoclonal antibody that targets the Zika virus (ZIKV) envelope (E) protein, specifically exhibiting neutralizing activity against ZIKV. It demonstrates potent inhibition of ZIKV E protein-mediated membrane fusion and neutralizes ZIKV African strains with an IC50 of 93 ng/ml. While effective against ZIKV in vitro, ZKA78 cross-reacts with dengue virus (DENV) and only partially neutralizes ZIKV infection, potentially promoting antibody-dependent enhancement (ADE) in vivo, as evidenced by severe symptoms and death in DENV-infected mice pretreated with ZKA78. It has been used as a positive control in studies assessing ZIKV neutralization in cell models like U937 cells.[3][4][7]

Other names: ZKA78ZKA-78ZKA 78

Targets

ZIKV E (Zika virus envelope protein)

Beyond the preview

Go deeper on ZKA78.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZKA78.

Explore the full profile